Table 4.
Base case (dis-)utility values for events up to 90 days.
| Mean (dis-)utility | SE(a) | Source | |
|---|---|---|---|
| No event (baseline utility at 90 days) | THR: 0.579 (BLU-THR) | 0.057 | PROMS 2014–2015 (Hunt, 2016) |
| TKR: 0.582 (BLU-TKR) | 0.058 | PROMS 2014–2015 (Hunt, 2016) | |
| Asymptomatic DVT- Distal | THR: 0.579 (BLU-THR) | 0.057 | PROMS 2014–2015 (Hunt, 2016) |
| Asymptomatic DVT- Proximal | TKR: 0.582 (BLU-TKR) | 0.058 | PROMS 2014–2015 (Hunt, 2016) |
| Symptomatic DVT- Proximal | −14% | Cohen 2014 (Barco et al., 2016) | |
| Symptomatic DVT- Distal (requiring treatment) | −14% | Assumption: equal to the disutility for symptomatic DVT-proximal | |
| Symptomatic DVT- Distal (not requiring treatment) | −7% | Assumption: equal to the 50% of the disutility for symptomatic DVT-proximal | |
| Non-fatal PE | −19% | Cohen 2014 (Barco et al., 2016) | |
| Warfarin treated DVT or PE | −0.012 | Marchetti 2001 (White et al., 2015) and Edoxaban TA354 (Cohoon et al., 2015) company submission | |
| Major bleeding (surgical site, GI with or without intervention, other) | −32% | Locadia 2004 (ISTH Steering Committee for World Thrombosis Day, 2014) | |
| ICH/acute stroke | −65% | Locadia 2004 (ISTH Steering Committee for World Thrombosis Day, 2014) | |
| Pre- aseptic revision surgery | THR: 0.399 | 0.039 | PROMS 2014–2015 (Hunt, 2016) |
| TKR: 0.329 | 0.033 | PROMS 2014–2015 (Hunt, 2016) | |
| Post-aseptic revision surgery | THR: 0.538 | 0.054 | PROMS 2014–2015 (Hunt, 2016) |
| TKR: 0.459 | 0.046 | PROMS 2014–2015 (Hunt, 2016) | |
| Post-reoperation for surgical site MB | THR: 0.538 | 0.054 | Assumed equal to post-aseptic revision |
| TKR: 0.459 | 0.046 | Assumed equal to post-aseptic revision | |
| CRNMB (including wound haematoma) | −0.03 | Sullivan 2011 (National Clinical Guideline Centre, 2010) | |
| Surgical site infection | −66% | Baker 2013 (Roberts et al., 2013) for TKR, assumed the same for THR | |
| Post-infected revision/return to theater for surgical site infection | −30% | Baker 2013 (Roberts et al., 2013) for TKR, assumed the same for THR | |
| HIT | −0.0712 | Gould 1999 (Gould et al., 2012) | |
| Post-HIT amputation | −0.28 | Beaudet 2014, T1D GL (Dahl et al., 2010) | |
| Post-HIT thrombosis | −16.5% | Assumed average of PE and symptomatic proximal DVT dis-utilities | |
| Post-HIT MB | −32% | Assumed equal to Major bleeding (surgical site, GI with or without intervention, other) |
BLU, baseline utility; CRNMB, clinically-relevant non-major bleeding; GI, gastrointestinal; HIT, heparin-induced thrombocytopaenia; ICH, intracranial hemorrhage; MB, major bleeding; PE, pulmonary embolism; SE, standard error; THR, total hip replacement; TKR, total knee replacement.
a Where not reported; SE was calculated as 10% of the mean.